TG Therapeutics ( (TGTX) ) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, with a particular emphasis on therapies for multiple sclerosis. In its latest earnings report, TG Therapeutics announced a strong third quarter for 2025, with total revenue reaching $161.7 million, driven primarily by the success of its product BRIUMVI in the U.S. market. The company has raised its full-year revenue guidance to $600 million, reflecting continued strong demand for BRIUMVI. Key financial highlights include a significant increase in net income to $390.9 million for the quarter, largely due to a non-recurring income tax benefit. The company also reported substantial growth in product revenue, with BRIUMVI U.S. net revenue experiencing an 84% increase compared to the same period in 2024. Additionally, TG Therapeutics has expanded its commercialization efforts internationally and achieved several pipeline development milestones. Looking ahead, TG Therapeutics remains focused on expanding patient awareness, advancing clinical trials, and driving long-term shareholder value, as indicated by the authorization of an additional $100 million share repurchase program.